Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNephrologyAetna selected kidney function tests Coverage | Op…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0775

    Selected Kidney Function Tests

    Customize your policy alerts

    Sign up for Aetna Policy 0775 alerts

    Get alerted when Policy 0775 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage stance for a set of selected kidney function tests and assays (including which tests are considered experimental/investigational) for Aetna members and the clinical contexts in which they are addressed.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerAetna
    PolicySelected Kidney Function Tests
    Policy CodePolicy 0775
    Change TypeNo material changes
    Effective DateFeb 6, 2009
    Last ReviewOct 11, 2023
    Next Review DateAug 22, 2024
    Key ActionLimit APOL1 genotyping and other novel renal tests to informed, targeted use in high-risk patients and document clinical indications when billing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    0775Policy #
    ~7%Adults ≥20 w/ CKD
    10–15%High‑risk APOL1 prevalence
    0.77KidneyIntelX AUC
    61%KidneyIntelX PPV (high)

    Coverage Criteria and Evidence Summary

    Experimental / Investigational

    The following tests are considered experimental and investigational because their effectiveness has not been established:

    Experimental/Investigational Tests: Apolipoprotein L1 (APOL1) renal risk variant genotyping (blood or buccal mucosa); GFRNMR test (metabolite-based NMR panel for GFR estimation); KidneyIntelX prognostic test for diabetic kidney disease; NaviDKD risk prediction test; PromarkerD prognostic/diagnostic test; RenalVysion urine cytology-based test; use of a transdermal system with pyrazine‑based fluorescent agents (e.g., MB-102) for measurement of glomerular filtration rate.

    Listed tests are considered experimental and investigational in the policy text.

    Recommended approach for APOL1 genotyping (research/clinical practice suggestions)

    Testing and use considered appropriate when ALL of the following are met (inferred from text):

    Informed, targeted testing: Patient is high-risk (for example, has CKD or HIV) and specifically desires APOL1 genetic testing after receiving counseling about potential benefits, limitations, and trade-offs.

    Policy text advises prudence and limiting APOL1 testing to high-risk individuals who provide informed consent.

    Result disclosure with support: Test results (APOL1) are disclosed to patients and clinicians accompanied by patient-centered counseling and clinical decision support (for example, EHR CDS) to guide blood pressure management and kidney disease screening.

    Based on randomized pilot study procedures and policy recommendation to pair testing with disclosure and CDS.

    Evidence and performance summaries

    Evidence-based findings and performance characteristics from cited studies

    APOL1 evidence summary: APOL1 genotyping: cohort and survey studies report receptivity to testing and variable prevalence of high-risk genotypes (example: 17% with 2 risk alleles in one nephrology cohort); impact on clinical outcomes remains uncertain and no targeted therapies are currently established; further prospective research and validation are recommended.

    Summarizes cohort/survey data and the policy's call for additional research.

    Polygenic and GPS findings: Combining APOL1 risk genotypes with a genome-wide polygenic score improved prediction across ancestries; the top 2% of the GPS was associated with nearly three-fold increased CKD risk; methods require further testing before clinical deployment.

    Based on Khan et al (2022) findings.

    KidneyIntelX diagnostic performance: KidneyIntelX (random-forest model using plasma sTNFR1, sTNFR2, KIM-1 plus EHR variables) demonstrated AUC 0.77 in derivation and validation cohorts, stratified patients into low/intermediate/high risk with a high-risk PPV of 61% and low-risk NPV of 90%, and improved reclassification versus KDIGO and clinical models.

    Derived from Chan et al and validation cohort performance metrics.

    Evidence-based coverage considerations

    Coverage considerations based on evidence and stated limitations

    PromarkerD evidence: PromarkerD: external validation studies show prognostic ability for incident CKD in type 2 diabetes (e.g., CANVAS sub-study) but limitations include predominately Caucasian cohorts, use of baseline-only biomarker data, limited performance for some outcomes (e.g., eGFR decline ≥30%), and NICE-identified 'key uncertainties' about how test use changes management and outcomes; further diverse validation and outcome-impact studies are needed before routine coverage.

    Summarizes PromarkerD limitations and NICE conclusions.

    GFRNMR evidence: GFRNMR: metabolite-based panels showed improved accuracy versus eGFRcr in development and some validation cohorts (examples: higher proportion within 30% of mGFR), but evidence is proof‑of‑concept and requires larger, diverse external validation and evaluation of non-GFR determinants of metabolites prior to coverage as a replacement for standard eGFR measures.

    Reflects Coresh et al and Ehrich et al study findings.

    Transdermal fluorescent GFR (MB-102): Transdermal MB-102 systems: preclinical and early human pilot data demonstrate feasibility and tracer properties supportive of bedside real‑time GFR measurement, but evidence is preliminary (small pilot studies, unpublished or limited human data) and insufficient to establish clinical effectiveness across patient populations; larger comparative clinical trials are required.

    Investigational / early clinical evidence

    Summary of available evidence and status

    Investigational development and early human testing: Verification and animal-model validation of the transdermal fluorescence device showed signal‑to‑noise ratios enabling ~5% precision in renal clearance estimates; MB-102 has favorable physicochemical and manufacturing properties (low plasma protein binding ~4.1%, minimal RBC distribution, stability, >95% purity); a small FDA‑approved pilot human study (n=16) using the MediBeacon/Brilliance device has been completed but results remain unpublished — overall evidence remains investigational.

    Describes device verification, MB-102 analytic properties, and early human pilot trial status.

    RenalVysion (Nephrocor) is a marketed urine-based “liquid biopsy” that combines urine cytopathology with urine chemistries (creatinine, protein, beta-2 microglobulin, microalbumin). However, there are no published studies demonstrating its performance for diagnosing or monitoring kidney disease and no professional society recommends its use for these indications. Randomized controlled studies comparing RenalVysion to standard approaches (proteinuria, hematuria, and eGFR measurement) are needed before it can be considered established for clinical use.

    Routine screening of unselected populations with APOL1 genotyping or other investigational kidney-risk tests is not supported by the available evidence. The policy advises that testing be considered primarily for high-risk individuals (for example, persons with CKD or HIV) and only after an informed discussion of potential advantages and trade‑offs. This prudent, targeted approach reflects insufficient evidence to recommend population-level screening at this time.

    Mayo Clinic Laboratories has stated that the currently available APOL1 genotype assay (“APOL1 Genotype, Varies”) is not useful for clinical management of individuals with APOL1 risk genotypes. This position underscores the limited current clinical utility of APOL1 genotyping outside selected research or high‑risk, counseled settings.

    NaviDKD is a biomarker-based blood test intended to predict long-term diabetic kidney disease risk, but it has not been cleared by the U.S. Food and Drug Administration and there are no published peer‑reviewed studies demonstrating its effectiveness. Given the absence of external validation and regulatory clearance, NaviDKD is unsupported for routine coverage based on the current evidence presented in this document.

    Multiple emerging tests (metabolite panels such as GFRNMR, biomarker panels like PromarkerD, and other proprietary algorithms) have not been validated across diverse racial/ethnic populations and clinical settings. The authors and reviews cited note limitations including homogeneous cohorts, limited sample sizes, storage/assay variability, and lack of demonstrated impact on clinical management or patient outcomes. Because generalizability and clinical utility have not been established, these tests remain investigational.

    The transdermal GFR measurement system using the MB‑102 fluorescent tracer and the Brilliance (MediBeacon) device has been evaluated in early human pilot work and a completed clinical trial, but the findings have not been published. The provided text does not include any explicit policy coverage exclusions for this transdermal system in the sections reviewed.

    Select novel biomarker assays and proprietary algorithm-based tests are listed as experimental and investigational in this policy and therefore considered not established for the indications addressed. Examples specifically named include KidneyIntelX, PromarkerD, NaviDKD, GFRNMR, APOL1 genotyping, RenalVysion, and the use of transdermal systems with pyrazine‑based fluorescent agents for GFR measurement.

    There is insufficient evidence to support widespread APOL1 genotyping outside of targeted, informed testing in patients at higher risk (for example, those with CKD or HIV) who opt for testing after counseling. Guidance in the source emphasizes prudence given uncertain impact on outcomes, limited management interventions, and variable generalizability of existing data.

    Certain candidate biomarker panels have demonstrated low incremental predictive power in validation studies. For example, analysis of a 17‑marker panel found that although several markers were associated with eGFR decline, their individual contribution beyond clinical predictors was small and overall predictive power was low — suggesting such panels are unlikely to be useful for routine clinical decision‑making without further development and validation.

    The National Institute for Health and Care Excellence (NICE) review concluded there are key uncertainties about PromarkerD, noting limited evidence and a need for studies that demonstrate how test results lead to changes in management and improved patient outcomes. These unresolved questions imply PromarkerD currently has limited evidence and may be considered not medically necessary for routine use until stronger validation and outcome data are available.

    The sections reviewed list multiple technologies as investigational or describe early-stage evidence, but they do not uniformly include explicit “not medically necessary” declarations for every technology discussed. For example, while several tests are labeled experimental/investigational, the text does not provide an explicit not‑medically‑necessary statement for the transdermal fluorescent GFR measurement within the provided chunks.

    Codes, Risk Strata, and Score Cut-offs

    CPT/Proprietary codes cited for investigational/not-covered testsmixedNot Covered
    0105UNephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (ECLIA) of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) combined with longitudinal clinical data, including APOL1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (RKFD).
    0602TGlomerular filtration rate (GFR) measurement(s), transdermal, including sensor placement and administration of a single dose of fluorescent pyrazine agent.
    0603TGlomerular filtration rate (GFR) monitoring, transdermal, including sensor placement and administration of more than one dose of fluorescent pyrazine agent, each 24 hours.
    0259UNephrology (chronic kidney disease), nuclear magnetic resonance spectroscopy measurement of myo-inositol, valine, and creatinine, algorithmically combined with cystatin C (by immunoassay) and demographic data to determine estimated glomerular filtration rate (GFR), serum, quantitative (GFRNMR).
    0355UAPOL1 (apolipoprotein L1) (eg, chronic kidney disease), risk variants (G1, G2).
    0384UNephrology (chronic kidney disease), carboxymethyllysine, methylglyoxal hydroimidazolone, and carboxyethyl lysine by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and HbA1c and estimated glomerular filtration rate (GFR), with risk score reported for predictive progression to high-stage kidney disease (NaviDKD/PromarkerD category).
    0385UNephrology (chronic kidney disease), apolipoprotein A4 (ApoA4), CD5 antigen-like (CD5L), and insulin-like growth factor binding protein 3 (IGFBP3) by enzyme-linked immunoassay (ELISA), plasma, algorithm combining results with HDL, estimated glomerular filtration rate (GFR) and clinical data reported as a risk score for developing diabetic kidney disease (PromarkerD).
    ICD-10 codes referencedICD-10
    I10 - I16.2Hypertensive diseases
    N18.1 - N18.9Chronic kidney disease (CKD)
    N19Unspecified kidney failure
    N26.2Page kidney
    R10.0 - R10.13 R10.30 - R10.33 R10.84Abdominal pain
    R31.0Gross hematuria
    R60.0 - R60.9Edema, not elsewhere classified
    R94.4Abnormal results of kidney function studies
    E11.00 - E11.9Type II diabetes
    E11.21 - E11.29Type 2 diabetes mellitus with kidney complications
    1–10 of 12
    1/2
    KidneyIntelX risk strata
    Risk strataKidneyIntelX stratifies patients into Low, Intermediate, and High risk groups for 5-year progressive DKD outcomes.
    High-risk PPVHigh-risk group positive predictive value (PPV) for progressive decline: 61%.
    Low-risk NPVLow-risk group negative predictive value (NPV) for progression: 90%.
    AUC performanceArea under the curve (AUC) in derivation and validation cohorts: 0.77.
    Risk distribution (validation)Validation cohort stratified into ~46% low-, 37% intermediate-, and 17% high-risk using derivation cut-offs.
    PromarkerD prognostic score cut-offs

    Provider Actions, Prior Authorization, and Billing Guidance

    Billing Rule

    Billing and Coding — Unsupported/Not Covered Test Codes

    Certain novel renal tests listed in this policy are identified as experimental/investigational and CPT codes for these tests are not covered when billed for the indications in this CPB. When ordering or billing, providers should support medical necessity in the chart and ensure documentation aligns with the clinical indication.

    • CPT codes listed in the policy (e.g., 0105U, 0259U, 0355U, 0384U, 0602T, 0603T, 0385U) are identified as NOT COVERED for the indications listed in this CPB.
    • ICD-10 diagnosis codes noted in the policy (examples: I10–I16.2, N18.1–N18.9, N19, E11.00–E11.9, E11.21–E11.29) are referenced as not covered for the CPB-listed indications — confirm the applicable diagnosis supports testing before billing.
    • If testing is pursued, document the clinical indication and supporting data (e.g., CKD stage, uACR, eGFR, diabetes status) in the medical record to justify medical necessity.

    Background and Scope

    Chronic kidney disease (CKD) is common, often asymptomatic, and routinely detected by measurements of proteinuria, hematuria, and estimated GFR. Novel assays and devices are being developed to improve risk prediction and GFR assessment, but many lack peer‑reviewed evidence, regulatory clearance, or demonstrated impact on management. The policy highlights the need for randomized or well‑validated comparative studies before these novel approaches can be recommended for routine clinical use.

    Definitions and Test Descriptions

    RenalVysion — definition
    Test descriptionRenalVysion is a urine-based test that integrates urine cytopathology with urine chemistries (creatinine, protein, beta-2 microglobulin, microalbumin).
    ManufacturerMarketed by Nephrocor (Glen Allen, VA).
    Evidence statusNo published studies support RenalVysion for kidney disease; no professional society recommends its use for diagnosis or monitoring.
    APOL1 renal risk variant genotyping — definition
    DefinitionAPOL1 renal risk variant genotyping tests for two coding variants (G1 and G2) in the apolipoprotein L1 gene associated with increased risk of CKD in individuals with recent West sub-Saharan African ancestry.
    Typical sample typesBlood or buccal mucosa specimens used for genotyping (as noted elsewhere in the policy).

    Policy Revision History

    2009-02-06effective

    Policy effective date established for Clinical Policy Bulletin No. 0775 (Selected Kidney Function Tests).

    2023-10-11last_reviewLatest

    Policy underwent last review (documented as Last Review: 10/11/2023).

    2024-08-22next_review
    Policy Summary
    PayerAetna
    PolicySelected Kidney Function Tests
    Policy CodePolicy 0775
    Change TypeNo material changes
    Effective DateFeb 6, 2009
    Last ReviewOct 11, 2023
    Next Review DateAug 22, 2024
    Key ActionLimit APOL1 genotyping and other novel renal tests to informed, targeted use in high-risk patients and document clinical indications when billing.
    SourceLink
    On This Page
    Coverage Criteria and Evidence SummaryCodes, Risk Strata, and Score Cut-offsProvider Actions, Prior Authorization, and Billing GuidanceBackground and ScopeDefinitions and Test DescriptionsPolicy Revision History
    Clinical impact observations: Implementation/real-world data indicate KidneyIntelX high-risk classification was associated with more clinic visits, increased initiation of SGLT2 inhibitors and specialist referrals, though effects on long-term hard outcomes remain to be established.

    Reflects reported associations between risk stratification and downstream care.

    Based on verification/validation studies, device pilot trial and MB-102 physicochemical data.

    Prognostic cut-offsPromarkerD prognostic score categories: <10% = Low risk; 10% to <20% = Moderate risk; ≥20% = High risk.
    Prognostic usePrognostic scores predict incident CKD and eGFR decline outcomes over follow-up (CANVAS sub-study and other validations).
    InputsPrognostic score combines three protein biomarkers (ApoA4, CD5L, IGFBP3) with clinical factors (age, HDL, eGFR).
    Score rangeScores represent predicted probabilities from 0% to 100% for renal outcomes.
    PromarkerD diagnostic score cut-offs
    Diagnostic cut-offsPromarkerD diagnostic score categories: <30% = Low; 30% to <60% = Moderate; ≥60% = High.
    Diagnostic useDiagnostic scores identify baseline prevalent CKD (diagnostic score uses same biomarkers but does not require baseline eGFR).
    Measurement methodProtein biomarkers measured by immunoaffinity targeted mass spectrometry in CANVAS sub-study analysis.
    Documentation Required

    APOL1 Genotyping — Informed Consent and High‑Risk Testing Only

    For APOL1 genotyping, testing is recommended only for high‑risk individuals after informed patient choice. Providers should obtain documented informed consent that includes discussion of benefits, limitations, potential psychosocial impact, and implications for treatment or future therapies.

    • Limit APOL1 genotype testing to high‑risk patients (e.g., patients with CKD, HIV, or other indications described in the policy) who explicitly opt in after counseling.
    • Document that the patient received counseling on test meaning, uncertainty about therapy changes, potential insurance/employment implications, and that testing was voluntary.
    • If future APOL1‑targeted therapies become available, documentation should include rationale linking genotype to therapy selection.
    Prior Authorization

    Prior Authorization — Not Specified in Policy

    The policy does not specify payer prior authorization requirements for APOL1 genotyping, KidneyIntelX, MediBeacon transdermal GFR measurement, or several other novel tests. Providers should verify current Aetna prior authorization policies and local medical management rules before ordering these tests.

    • No explicit prior authorization instructions are provided in this policy section — check payer portals or medical policy guidance for any authorization requirements prior to testing.
    • When prior authorization is not specified, submit supporting clinical documentation with claims to reduce denial risk (see billing/coding callout).
    Denial Risk

    NaviDKD — Prior Authorization Likely / High Denial Risk

    Some novel tests lacking FDA clearance or peer‑reviewed evidence (e.g., NaviDKD) are likely to require prior authorization and may be denied without robust clinical justification. Anticipate denials for tests with limited evidence of clinical utility.

    • NaviDKD: not FDA‑cleared and no peer‑reviewed effectiveness data — expect prior authorization requirements and probable noncoverage without documented investigational/ research context.
    • Provide detailed clinical rationale, prior therapy history, and any investigational protocol documentation if seeking coverage for NaviDKD.
    Denial Risk

    PromarkerD and Similar Tests — Prior Authorization Likely; Evidence Uncertainty May Trigger Noncoverage

    For PromarkerD and other prognostic protein‑biomarker panels, evidence uncertainty may prompt payers to require prior authorization or deny coverage. Use of these tests should be supported by documentation showing intended impact on management.

    • PromarkerD: limited evidence and NICE-identified uncertainties — anticipate prior authorization requests to demonstrate how results will change management and improve outcomes.
    • Document intended downstream actions (e.g., intensified monitoring, referral, medication changes) tied to test results when requesting authorization.
    Step Therapy

    GFRNMR and Transdermal GFR Measurement — Stepwise Testing Expectation

    Emerging metabolite‑panel GFR tests (GFRNMR) and transdermal MB‑102 approaches are at proof‑of‑concept or early clinical study stages and are not replacements for standard eGFR measures. Providers should expect stepwise testing expectations and limited coverage.

    • GFRNMR: considered investigational; if used, expect it to be an adjunct or research tool rather than a substitute for standard serum creatinine/cystatin C eGFR assessment.
    • Transdermal MB‑102 (MediBeacon): clinical trials completed but published outcomes limited; no explicit coverage or authorization guidance in this policy — verify payer rules before use.
    • Document standard eGFR and uACR results alongside any experimental test when submitting for review.
    Documentation Required

    Documentation and Clinical Data to Support Billing (uACR, eGFR, Intended Management)

    Support the clinical indication in the medical record when billing for any of the investigational tests listed. The KidneyIntelX studies noted that availability of urine albumin‑to‑creatinine ratio (uACR) improves predictive performance; include uACR and eGFR data in documentation when applicable.

    • Include contemporaneous uACR and eGFR values in the chart when ordering predictive tests (e.g., KidneyIntelX) because model performance depends on these inputs.
    • If KidneyIntelX or similar tests are ordered, document how results would change clinical management (e.g., SGLT2 initiation, specialist referral) to support medical necessity.
    • When billing investigational CPT codes, attach clinical notes, lab values, prior therapies, and informed consent (if genetic testing) to reduce denial risk.
    Note

    No Explicit Authorization/Coverage Instruction — Confirm with Payer

    Where the policy provides no explicit provider action or authorization rule for a given technology, contact Aetna medical policy or provider services for clarification and follow usual processes for investigational test review.

    • If no coverage/authorization guidance is available in the policy, obtain pre‑service confirmation from the payer.
    • Maintain clear documentation of attempts to obtain authorization and rationale for testing if performed under research or compassionate‑use contexts.
    Documentation Required

    KidneyIntelX — Document Downstream Management Changes

    KidneyIntelX results have been associated with downstream changes in care (increased SGLT2 inhibitor prescribing, referrals, and visit frequency). When using such tests, document intended and actual management changes to demonstrate clinical utility.

    • Document baseline therapy and any medication changes (e.g., SGLT2 initiation), referrals, or monitoring frequency that occur after testing to support clinical utility.
    • Include KidneyIntelX score and risk category in notes and link to specific management decisions when submitting prior authorization or appeal documentation.
    Prevalence noteApproximately 10–15% of African American individuals carry a high-risk APOL1 genotype (two risk variants).
    APOL1 high-risk genotype
    High‑risk genotype definitionPresence of two APOL1 renal risk alleles (G1 and/or G2), which is associated with increased risk of certain kidney diseases in individuals of recent African ancestry.
    Associated conditionsLinked to increased risk of focal segmental glomerulosclerosis (FSGS), HIV-associated nephropathy, hypertension‑attributed ESKD, and progression from CKD to ESRD.
    Risk magnitudeMeta-analysis reported RR for incident CKD ~1.41 and RR for progression from CKD to ESRD ~1.70 for high-risk versus low‑risk genotypes.
    Second hit — definition
    ConceptSecond hit refers to additional environmental or biological exposures (e.g., viral infection, interferon exposure, autoimmune disease, sickle cell disease, glomerular hyperfiltration) required for APOL1-associated kidney disease to manifest.
    Mechanistic noteUp‑regulation of APOL1 by interferons is identified as a potent second hit in pathophysiology discussions.
    ImplicationMost individuals with APOL1 high‑risk status do not develop disease without such second‑hit exposures; further study in diverse populations is recommended.
    APOL1 renal‑risk variants — definition
    DefinitionAPOL1 renal‑risk variants are specific genetic variants in the apolipoprotein L1 gene more common in individuals with African ancestry that, when present in two copies, are associated with higher risk of kidney disease progression.
    Clinical observationIn a cited nephrology cohort, 17% of genotyped individuals had two APOL1 renal‑risk variants.
    Research needFurther research is needed to determine optimal patient‑centered use and population‑level implications.
    KidneyIntelX (short definition)
    Short definitionKidneyIntelX is an AI‑enabled prognostic immunoassay and risk model combining plasma biomarkers (sTNFR1, sTNFR2, KIM‑1) with EHR clinical variables using a random forest algorithm to predict 5‑year risk of progressive kidney disease in diabetic kidney disease (DKD).
    AlgorithmRandom forest model integrating biomarker measurements and electronic health record data.
    Intended useDesigned to support physician decision‑making by improving identification, prediction, and risk stratification of patients with progressive DKD.
    KidneyIntelX — composite risk score
    Composite scoreKidneyIntelX produces a composite risk score that incorporates soluble TNFR‑1, TNFR‑2, KIM‑1 and clinical variables to predict DKD progression and stratify patients into low/intermediate/high risk.
    Validated performanceShown to improve prediction over KDIGO and clinical models (AUC 0.77; improved NRI and risk classification).
    Clinical observationsHigh‑risk KidneyIntelX results were associated with increased initiation of guideline medications (e.g., SGLT2 inhibitors) and referrals in real‑world analyses.
    PromarkerD — definition
    Test descriptionPromarkerD is a blood test that measures three protein biomarkers (apoA4, CD5L, IGFBP3) plus clinical factors (age, HDL‑cholesterol, eGFR) to predict future renal decline in type 2 diabetes.
    Score typesGenerates prognostic and diagnostic scores categorized into low/moderate/high risk using defined cut‑offs.
    Analytic methodBiomarkers measured by targeted mass spectrometry (immunoaffinity MS) in validation studies.
    NaviDKD — definition
    DefinitionNaviDKD is a biomarker‑based blood test measuring advanced glycation end products (AGEs) plus A1C and risk factors to predict long‑term DKD risk (reported as low/medium/high risk for 8–12 year risk).
    Regulatory statusNaviDKD has not been cleared by the U.S. Food and Drug Administration.
    Evidence statusNo published peer‑reviewed literature on effectiveness was available in the policy text.
    Serum uric acid (UA) — definition
    DefinitionSerum uric acid (UA) is a laboratory measurement associated in cohort studies and meta‑analyses with incidence and progression of CKD; very high levels (>15 mg/dL) may indicate acute uric acid nephropathy in specific settings.
    EvidenceMeta‑analysis of cohort studies shows lower UA levels are protective for CKD incidence and progression (pooled analyses cited).
    Clinical contextRole of urate‑lowering therapy to prevent CKD progression remains controversial.
    PromarkerD score — definition
    DefinitionPromarkerD score is the predicted probability (0–100%) of renal outcomes (incident CKD, eGFR decline ≥30%, or baseline CKD) derived from clinical variables plus three protein biomarkers and categorized into risk strata.
    Prognostic cut-offsPrognostic cut‑points: 10% and 20% for low/moderate/high categories; diagnostic cut‑points: 30% and 60%.
    Validation performanceIn validation cohorts PromarkerD showed AUC up to 0.88 for incident DKD in FDS2 and varied PPV/NPV depending on outcome and cut‑offs.
    GFRNMR — definition
    DefinitionGFRNMR is a serum‑based NMR metabolite panel combining metabolites such as myo‑inositol, dimethyl sulfone, valine, and creatinine (with cystatin C/demographic data) to estimate glomerular filtration rate.
    Analytic platformUses nuclear magnetic resonance spectroscopy to measure metabolite concentrations for GFR estimation.
    Development statusProof‑of‑concept/validation in selected cohorts; further diverse validation recommended.
    MB-102 / transdermal fluorescent GFR — definition
    DefinitionMB‑102 is an exogenous pyrazine‑based fluorescent tracer agent administered intravenously for transdermal point‑of‑care measurement of GFR; its clearance is detected by skin‑mounted sensors to estimate GFR in near real‑time.
    Tracer propertiesMB‑102 has strong UV absorbance (266 nm, 435 nm), emission ~560 nm when excited ~440 nm, low plasma protein binding (~4.1%), minimal RBC distribution (blood‑to‑plasma ratio 0.590), stability at 2–8°C >3 years, and manufacturing purity >95%.
    EvidenceAnimal validation and an FDA‑approved pilot human study (16 subjects) support feasibility; larger clinical outcome studies are lacking.
    Brilliance device / MediBeacon Transdermal GFR Measurement System — definition
    Device descriptionBrilliance device (MediBeacon Transdermal GFR Measurement System) is a skin‑mounted fluorescence detection system intended to noninvasively monitor MB‑102 emission over time to measure GFR at the bedside in near real‑time.
    Clinical testingDevice prototype verification and animal validation supported progression to an FDA‑approved pilot human study; a clinical trial of tolerability/background fluorescence has been completed but results are unpublished.
    Use caseDesigned for point‑of‑care, near real‑time GFR assessment using transdermal fluorescence detection of MB‑102 clearance.

    Next scheduled policy review date set (Next Review: 08/22/2024).